Sight Sciences, Inc.

SGHT Nasdaq SEC CIK 1531177
Follow Sight Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $24.9M +25.2% vs same quarter last year
Net income −$6.8M +16.6% vs same quarter last year
EPS, diluted −$0.12 +25% vs same quarter last year
Operating cash flow −$2.4M +72.5% vs same quarter last year
Revenue by quarter
$19.1M
$17.5M
$19.6M
$19.9M
$20.4M
$19.7M
$23.4M
$24.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50M$100MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$77.4M−$38.4M
FY24$79.9M−$51.5M
FY23$81.1M−$55.5M
FY22$71.3M−$86.2M
FY21$49M−$63M
FY20$27.6M−$34.7M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2586.2%−48%−49.7%
FY2485.5%−63.3%−64.5%
FY2385.3%−70.7%−68.5%
FY2282.7%−117.7%−120.9%
FY2182.4%−105.2%−128.6%
FY2066.7%−116.5%−125.5%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$29.9M
FY24−$22.7M
FY23−$48M
FY22−$76.9M
FY21−$53.4M
FY20−$33.1M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Sight Sciences
  • Healthcare median
−150%−100%−50%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearSight SciencesHealthcare median
FY25−49.7%−30.6%
FY24−64.5%−47%
FY23−68.5%−58%
FY22−120.9%−80.4%
FY21−128.6%−71.8%
FY20−125.5%−62.2%
FY19-−46.2%